Safety and tolerability of antidepressants: Weighing the impact on treatment decisions

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 8, 2007, Pages 26-34

  Schatzberg, Alan F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; DOXAZOSIN; DULOXETINE; FENFLURAMINE; FLUOXETINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LABETALOL; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; PRAZOSIN; REBOXETINE; SELEGILINE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERAZOSIN; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANTICHOLINERGIC EFFECT; ANXIETY; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; BLURRED VISION; CARDIOPULMONARY INSUFFICIENCY; CARDIOTOXICITY; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLUID INTAKE; FLUSHING; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEART BEAT; HEART DISEASE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERPYREXIA; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER FAILURE; LOW DRUG DOSE; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MEMORY DISORDER; MENSTRUAL CYCLE; META ANALYSIS; MOTOR DYSFUNCTION; MYDRIASIS; NAUSEA; NERVOUSNESS; NONHUMAN; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIAPISM; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; RECOMMENDED DRUG DOSE; REVIEW; SALT INTAKE; SEDATION; SEIZURE; SENSATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SOMNOLENCE; STIMULATION; SUICIDE ATTEMPT; SWEATING; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; UNCONSCIOUSNESS; URINARY HESITANCY; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PATIENT COMPLIANCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34547534646     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-3105
2. Wells KB, Stewart A, Hayes RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989;262:914-919
3. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-743
4. Stein MB, Cox BJ, Afifi TO, et al. Does co-morbid depressive illness magnify the impact of chronic physical illness? a population-based perspective. Psychol Med 2006;36:587-596
5. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-418
6. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res 2002;53:849-857
7. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
8. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-636
9. Masand P, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002;14:175-182
10. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76:511-527
11. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30-34
12. Dording CM, Mischoulon D, Peterson TJ, et al. The pharmacological management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002;14:143-147
13. Arima Y, Kubo C, Tsujimoto M, et al. Improvement of dry mouth by replacing paroxetine with fluvoxamine. Ann Pharmacother 2005;39:567-571
14. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998;13(suppl 5):S25-S30
15. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-491
16. Therapeutic options in treating depression. US Pharmacist. January 2001
17. Nemeroff CB, Devane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
18. Mahwhinney M, Cole D, Azzaro AJ, et al. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared to intestinal and hepatic tissues. J Pharm Pharmacol 2003;55:27-34
19. Wecker L, James S, Copeland N, et al. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003;54:1099-1104
20. Sporer KA. The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Saf 1995;13:94-104
21. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-88
22. Holschneider DP, Shih JC. Monoamine oxidase: basic and clinical perspectives. In: Psychopharmacology: The Fourth Generation of Progress. Nashville, Term: American College of Neuropsychopharmacology; 2000
23. Potter WZ, Rudorfer MV, Manji HK. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-642
24. Hyman SE, Rudorfer MV. Depressive and bipolar mood disorders. In: Dale DC, Federman DD, eds. Scientific American Medicine. New York, NY: Healtheon/WebMD; 2003
25. Mulrow CD, Williams JW Jr, Trivedi M, et al. Treatment of depression: newer pharmacotherapies. Psychopharmacol Bull 1998;34:409-795
26. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999;60(suppl 4):14-21
27. Perry JP. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996;39:1-5
28. Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999;60:326-335
29. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988;26:265-271
30. Fernstrom MH, Krowinski RL, Kupfer DJ. Chronic imipramine treatment and weight gain. Psychiatry Res 1986;17:269-273
31. Fernstrom MH, Kupfer DJ. Imipramine treatment and preference for sweets. Appetite 1988;10:149-155
32. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight during the treatment of recurrent depression. Psychiatr Ann 1999;29:580-594
33. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996;14:329-342
34. Fernstrom MH. Depression, antidepressants, and body weight change. Ann N Y Acad Sci 1989;575:31-39
35. Levitt AJ, Joffe RT, Esche I, et al. The effect of desipramine on body weight in depression. J Clin Psychiatry 1987;48:27-28
36. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61(suppl 11):37-41
37. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994;55(suppl A):83-87
38. Glauser J. Tricyclic antidepressant poisoning. Cleve Clin J Med 2000;67:704-706, 709-713, 717-719
39. Abies AZ, Baughman OL 3rd. Antidepressants: update on new agents and indications. Am Fam Physician 2003;67:547-554
40. Stahl SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry 1998;59:343-344
41. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53(suppl):61-66
42. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994;9(suppl 1):19-26
43. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170-1176
44. Mackle M, Kocsis J. Effects of body weight of the SSRI citalopram. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998; Las Croabas, Puerto Rico
45. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867
46. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000;20:645-652
47. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000;61(suppl 11):28-36
48. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. Antidepressant- induced sexual dysfunction: a multicenter and prospective study using a questionnaire of 693 patients. Presented at the 152nd annual meeting of the American Psychiatric Association; May 20, 1999; Washington, DC
49. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-281
50. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
51. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-1516
52. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624
53. Arias F, Padin JJ, Gilaberte I. Comparative efficacy and tolerability among different selective serotonin reuptake inhibitors and venlafaxine in a naturalistic setting. Int J Psych Clin Pract 1998;2:255-260
54. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol 1998;18:19-25
55. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-508
56. Hirschfeld RM, Vomik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004;65(suppl 4):46-52
57. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-132
58. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692
59. Hellerstein DJ, Batchelder S, Kreditor D, et al. Bupropion sustained release for the treatment of dysthymic disorder: an open-label study. J Clin Psychopharmacol 2001;21:325-329
60. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 2004;16:15-25
61. Branconnier RJ, Cole JO, Ghazvinian S, et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry 1983;44:130-133
62. Golden RN, Dawkins K, Nicholas L, et al. Trazodone, nefazodone, bupropion, and mirtazapine. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology, 2nd ed. Washington, DC: American Psychiatric Press; 1998
63. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
64. US Food and Drug Administration. Serzone black box warning. 2002. Available at: http://www.fda.gov/cder/foi/label/2002/20152slr009lbl.pdf. Accessibility verified April 17, 2007
65. Stimmel GL, Sussman N, Wingard P. Mirtazapine safety and tolerability: analysis of clinical trials database. Prim Psychiatry 1997;6:82-90
66. Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000;20:531-537
67. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl 1997;391:31-37
68. Kent JM. SNaRIs, NaSSAs and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-918
69. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000;61(suppl 10):31-38
70. Nierenberg AA, Keck PE Jr. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989;9:42-45
71. DeBattista C, Solvason B, Poirier J, et al. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry 2005;66:844-848
72. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006;67(suppl 4):3-7
73. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001;24:183-197
74. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
75. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br J Psychiatry 2000;176:363-368
76. Schatzberg AF, Blier P, Delgado PL, et al. Antidepression discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006;67(suppl 4):27-30
77. Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 1997;58(suppl 7):5-10
78. FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. FDA News. P04-97, Oct 15, 2004. Available at: http://www.fda.gov/bbs/topics/news/2004/NEW01124.html. Accessibility verified April 17, 2007
79. DeGroot MJ. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov Today 2006;11:601-606
80. McConathy J, Owens MJ, Kilts CD, et al. Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. Nucl Med Biol 2005;32:593-605
81. Carlier PR, Lo MM, Lo PC, et al. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol function group. Bioorg Med Chem Lett 1998;8:487-492
82. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809
83. Murphy GM Jr, Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-1835
84. Murphy GM Jr, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-1169